Your browser doesn't support javascript.
loading
[Carcinoembryonic type specific markers and liver cancer immunotherapy].
Yao, M; Yang, J L; Wang, L; Yao, D F.
Afiliação
  • Yao M; Department of Immunology, Medical School of Nantong University, Nantong 226001, China.
  • Yang JL; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China.
  • Wang L; Department of Informatics, Medical School of Nantong University, Nantong 226001, China.
  • Yao DF; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China.
Zhonghua Gan Zang Bing Za Zhi ; 28(6): 466-470, 2020 Jun 20.
Article em Zh | MEDLINE | ID: mdl-32660172
Hepatocellular carcinoma (HCC) is a chronic inflammation derived from the background of hepatitis B and C virus (HBV and HCV) infection, chemical intoxicants, or non-alcoholic fatty liver disease. Cancerous liver cells can express and secrete a variety of relatively specific markers, such as carcinoembryonic type of alpha-fetoprotein (AFP), phosphatidylinositol-3 (Glypican-3, GPC-3), Wnt/ß-Catenin key molecule of signaling pathway Wnt3a and liver cancer specific GGT-II (HS-GGT), etc. Clinical analysis of carcinoembryonic markers not only contributes to diagnosis and prognosis of HCC, but may also be the target of HCC immunotherapy with a promising prospect of development and application. This article reviews the latest valuable advances in carcinoembryonic type specific molecular markers and liver cancer immunotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Imunoterapia / Neoplasias Hepáticas Limite: Humans Idioma: Zh Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Imunoterapia / Neoplasias Hepáticas Limite: Humans Idioma: Zh Ano de publicação: 2020 Tipo de documento: Article